According to the EvaluatePharma review of biotech and pharma industry in 2012, four out of five top biotech launches are not selling as expected.
The report also addresses the record number of FDA approvals of novel medicines (43 in 2012) and analyses market performance, VC funding, licensing deals, M&A transactions etc.
Read the press release or download the review here.
Cover image: Pills (Photobucket).
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 847
- Comments 0